Could Merck (MRK) Reset Endometrial Cancer Care With Two Phase 3 Wins?

• Merck (NYSE:MRK) reported new Phase 3 data for sacituzumab tirumotecan and KEYTRUDA in advanced or recurrent endometrial cancer, highlighted at a major oncology congress and in The Lancet.
• The TroFuse-005 trial showed sacituzumab tirumotecan outperformed chemotherapy in this setting, the first antibody drug conjugate to do so for these patients.
• KEYNOTE-C93 data indicated that KEYTRUDA monotherapy achieved statistically significant gains in survival and disease control without chemotherapy for advanced endometrial cancer.
• The FDA granted priority review to Merck's Biologics License Application for sacituzumab tirumotecan, reflecting potential for earlier regulatory action.
• The sacituzumab tirumotecan and KEYTRUDA Phase 3 wins only capture part of what Merck's evolving oncology pipeline could mean. Our analysis turns up 5 warning signs for Merck as well.

Investors tracking Merck's latest oncology readouts may also want to compare these results with other large drug developers in the same cancer space through 30 resilient stocks with low risk scores.

Merck operates as a global healthcare group focused on pharmaceuticals, and the endometrial cancer readouts connect directly to its broader oncology franchise. This includes KEYTRUDA as a core immunotherapy platform that management is working to extend across multiple tumor types.

2 things going right for Merck that this headline doesn't cover.

How do sac-TMT and KEYTRUDA reshape Merck's market opportunity in endometrial cancer?

TroFuse-005 positions sacituzumab tirumotecan in previously treated advanced endometrial cancer, where it reduced risk of death by 32% and progression or death by 41% versus chemotherapy. KEYNOTE-C93 targets earlier dMMR disease, with KEYTRUDA monotherapy cutting progression or death risk by 43% and extending median progression free survival to 38.2 months versus 8.4 months. Together, they give Merck potential exposure across both front line and relapsed settings in this tumor type.

Does this change the Merck Narrative around the post KEYTRUDA period?

The Narrative already leans on sac TMT and KEYTRUDA based regimens as part of more than 20 planned growth drivers that analysts see supporting revenue once KEYTRUDA faces loss of exclusivity. Statistically significant overall survival and progression free survival gains in TroFuse-005 and prolonged chemotherapy free disease control in KEYNOTE-C93 support the view that Merck's oncology pipeline can supply multiple franchises rather than a single flagship product.

See how these catalysts shape Merck's path to a $160 fair value.

What should you watch next to see if this Merck oncology push is gaining real traction?

The clearest check from here is how quickly regulators act and how treatment uptake starts to show up in reported numbers. The FDA priority review for sac TMT comes with a June 15, 2027 PDUFA date. Investors can watch quarterly updates from late 2027 onward for early contribution from endometrial cancer, alongside any new guidance on KEYTRUDA monotherapy use in dMMR disease.

Add Merck to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com